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Abstract
Little is known about the psychosocial impact of antiretroviral therapy (ART) among women in 
sub-Saharan Africa. Therefore, we conducted a cross-sectional study in Zimbabwe to assess the 
impact of ART on HIV-positive women’s health-related quality of life, using the Medical 
Outcomes Study-HIV Quality of Life (QOL) questionnaire. Additionally, we assessed socio-
demographics, reproductive and sexual health, HIV-related history, disclosure, social stigma, self-
esteem, and depression. Structured interviews were conducted with 200 HIV-positive women and 
categorized into three groups by treatment: (1) Group 1 (n = 31) did not meet clinical or laboratory 
criteria to begin treatment; (2) Group 2 (n = 73) was eligible to begin treatment but awaiting 
initiation of treatment; and (3) Group 3 (n = 96) was on ART for a median of 13 months. The 
women had similar sociodemographic characteristics but varied significantly in clinical 
characteristics. Women on ART reported fewer AIDS-related symptoms in the last week and year 
and had higher current and lower baseline CD4 counts compared to women not on ART. On most 
QOL domains women on ART reported higher mean scores as compared to women not on ART 
( p<0.01). Additionally, women on ART reported less depression compared to women not on ART 
( p<0.001). Between the two groups of women not on ART, unexpectedly, there were no 
significant differences in their scores for QOL or depression. Thus, Zimbabwean women living 
with HIV experience better overall QOL and lower depression on ART. Altogether, our findings 
suggest that ART delivery in resource-poor communities can enhance overall QOL as well as 
psychosocial functioning, which has wide-ranging public health implications.
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Introduction
In Zimbabwe, an estimated 15.6% of adults are living with HIV/AIDS (UNGASS, 2008), 
reducing life expectancy to 34 years for women (World Health Organization, 2005). 
Increasing access to antiretroviral therapy (ART) offers hope. In 2007, approximately 20% 
of infected women needing ART in Zimbabwe were receiving treatment. Although the long-
term goal of ART is to restore health and improve quality of life (QOL) for people living 
with HIV/AIDS (PLWHA), little is known about the effects of ART on QOL and 
psychosocial health among women, particularly in sub-Saharan Africa (SSA).
HIV and quality of life (QOL)
Health-related quality of life (HR-QOL) is a multidimensional construct for patients’ 
perceived well-being, centered on physical, mental, and social functioning (Smith, Avis, & 
Assmann, 1999). Several measures capture HR-QOL (Wu, 2000) and changes in QOL in 
PLWHA initiating ART has been studied in Western settings (Jia, Uphold, Wu, Chen, & 
Duncan, 2005; Liu et al., 2006; Murri et al., 2003). Nonetheless, which socio-economic, 
psychosocial, and clinical factors mediate perceived HR-QOL in PLWHA is unclear.
Several studies have demonstrated the feasibility and efficacy of ART in resource-poor 
settings (Djomand et al., 2003; Laurent et al., 2005; Sow et al., 2007) but only recently have 
studies focused on HR-QOL in patients on treatment (Ichikawa & Natpratan, 2006; Jelsma, 
Maclean, Hughes, Tinise, & Darder, 2005; Poupard et al., 2007; Stangl, Wamai, Mermin, 
Awor, & Bunnell, 2007). In South Africa, Jelsma et al. (2005) demonstrated a significant 
increase in HR-QOL among HIV-positive patients after 12 months of ART in a public sector 
program. The most comprehensive HR-QOL research in SSA by Stangl et al. (2007) 
prospectively followed 947 AIDS patients initiating treatment in rural Uganda. At study 
entry depression, lower CD4 counts, higher HIV RNA levels, economic dependence, and 
lower education predicted lower initial HR-QOL but economic dependence was the sole 
predictor of lower HR-QOL at follow-up (Stangl et al., 2007).
Limited resources require prioritizing access to ART. QOL measures may add to biologic 
measures of ART response to assess resource allocation and health outcomes. Here, we 
examined socio-economic, psychosocial, and clinical measures among HIV-positive women 
living in Zimbabwe who were at different stages of initiating ART. We studied women 
because they constitute more than 80% of the ART recipients, consistent with the 
overrepresentation of women in treatment programs in Zimbabwe and generally in SSA 
(UNAIDS, 2008).
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Methods
Participants
Women were recruited between June and August 2007 at the opportunistic infections (OI) 
clinic at the Chitungwiza Regional Hospital, a national ART rollout site 25 km from Harare 
(Figure 1). Study eligibility included age >18 years, HIV infection, being on ART or on the 
“waiting list,” and ability to provide informed consent. Individuals enrolled in another study 
or who did not speak English, Shona, or Ndebele were excluded.
After informed consent was obtained, interviewers administered a one-hour questionnaire. 
Study nurses assessed participants’ current HIV-related symptoms and illnesses, and 
obtained blood samples. Laboratory results were provided to the participants and included in 
their medical records. The Stanford University Institutional Review Board and the Medical 
Research Council of Zimbabwe approved the study.
Measures
Socio-demographics, reproductive and sexual health, HIV-related history, disclosure, social 
stigma, self-esteem, depression, and QOL were assessed. “Baseline clinical data” including 
initial CD4 counts, WHO clinical staging, and duration on ART were obtained through chart 
review. The questionnaire was translated into Shona and back-translated into English. Three 
female interviewers were selected from the community and trained.
Disclosure—We modified the disclosure matrix in the Bauman Decision to Disclose Scale 
(Pequegnat et al., 2001) by adding more targets and choices on how they reacted to the 
disclosure.
Social stigma—We modified the 40-question HIV Stigma Scale (Berger, Ferrans, & 
Lashley, 2001) to include 11 questions in total and divided the scale into perceived and 
experienced stigma. Items were summed for a total score and higher scores indicate lower 
stigma. The Cronbach’s coefficient alphas for the two subscales were 0.80 (stigma 
perceived) and 0.74 (stigma experienced).
Self-esteem—The self-esteem scale was adapted for local context from the University of 
California at San Francisco Center for AIDS Prevention Studies (UCSF CAPS) HIV 
Counseling and Testing questionnaire (Coates et al., 2000). Higher scores indicate higher 
self-esteem. The Cronbach’s coefficient alpha was 0.76 for the scale.
Depression—The depression scale was adapted for local context from the UCSF CAPS 
HIV Counseling and Testing questionnaire validated in developing countries (Coates et al., 
2000). A second depression scale, the Shona Symptom Questionnaire (SSQ14) was used, 
which has been developed and validated among HIV-positive Zimbabweans (Nhiwatiwa, 
Patel, & Acuda, 1998; Patel, Simunyu, Gwanzura, Lewis, & Mann, 1997; Patel et al., 1998; 
Stranix-Chibanda et al., 2005). For both scales, higher scores indicate worse depressive 
symptoms. Questions about somatic symptoms were removed from analysis to avoid 
conflating symptoms of HIV disease with those of depression (Kalichman, Rompa, & Cage, 
2000). A second scale was used to further validate the SSQ14; the SSQ14 was the preferred 
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depression measurement tool because it was developed locally and thus culturally relevant. 
The Cronbach’s coefficient alphas were 0.75 for the depression scale and 0.86 for the 
SSQ14 and the total scores on the two scales had an alpha of 0.80.
Quality of life (QOL)—The Medical Outcomes Study-HIV (MOS-HIV) QOL 
questionnaire (Wu, Revicki, Jacobson, & Malitz, 1997) has been validated in Zimbabwe 
(Taylor, Dolezal, Tross, & Holmes, 2009) and other sub- Saharan settings such as Uganda 
(Mast et al., 2004). The instrument contains 11 subscales or domains of HR-QOL, including 
health perceptions, pain, physical functioning, role functioning, social functioning, mental 
health, vitality, health distress, cognitive functioning, health transition, and overall QOL. To 
impute missing values in subscales, averages were used when more than half the values 
were present; only six (0.001%) single values were missing for the MOS-HIV QOL data 
which were imputed as described above. The subscale scores were then transformed on a 0–
100 scale to have a mean of 50 and a standard deviation of 10, with higher scores 
representing better QOL (Revicki, Sorensen, & Wu, 1998). Factor analysis was used to 
construct summary scores of the MOS-HIV QOL questionnaire for physical and mental 
health (Revicki et al., 1998). The inter-reliability of the subscales was assessed using 
Cronbach’s coefficient alpha, which ranged from 0.62 (mental health) to 0.92 (health 
distress).
CD4 counts—Current CD4 T-lymphocytes were enumerated using Guava Easy-CD4 
(Guava Technologies, Hayward, CA) or BD FACSCount™ (Becton Dickinson, Mountain 
View, CA).
Data analysis
The study was designed to have 80% power with an alpha of 0.05 to detect a 15% increase 
in CD4 counts from baseline for the patients on ART. All statistical analyses were carried 
out using SAS version 9.1 (Cary, North Carolina). Chi-square (χ2) or Fisher’s exact tests 
were used to test categorical variables and ANOVA for continuous variables. A general 
linear model was used to adjust for confounding variables and a linear regression model to 
identify predictors of better QOL.
Certain continuous variables, such as household goods, number of people disclosed to, self-
reported signs and symptoms in the last year, duration of HIV, and SSQ14 were transformed 
into binary measures based on median cut-offs except for age, education, and CD4 levels.
The participants were classified into three groups (Figure 1) according to eligibility and 
receipt of ART. The eligibility criteria for starting treatment were based on WHO 2003 
recommendations when CD4 ≤ 200 cells/mm3 or at WHO stage 3 or 4 disease (World 
Health Organization, 2004). The first group of women (n = 31) were not eligible for 
treatment based on clinical or laboratory criteria. The second group (n = 73) were eligible 
for but not receiving ART, largely due to limited drug access. The third group (n = 96) were 
receiving ART. Therefore, Group 1 is termed INELIGIBLE, Group 2 WAITING, and Group 
3 TREATED groups. CD4 counts used for classification were based on the values obtained 
by the study and the WHO clinical staging criteria were recorded in the patients’ medical 
charts at baseline.
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Results
The median age of the women was 35 years (range 22–69 years). Seventy percentage had 
completed at least some secondary schooling and nearly all were literate. Thirty seven 
percentage were currently married and 45% reported being unemployed, which excluded 
self or informal employment. Approximately 47% of the women reported ever using a 
condom, and their median number of pregnancies was three with median age of sexual debut 
at 19 years. Women reported a median of two lifetime sexual partners and one in the past 
year. The median baseline and current CD4 counts were 176 and 254 cells/mm3, 
respectively, and 60% of the women reported a history of WHO clinical stage 3 or 4 disease.
The three groups of women were similar in baseline socio-demographic characteristics 
(Table 1). However, the mean age for the treated group of 36.4 years (median 37) was 
significantly greater than those for the ineligible and waiting groups of women, 35.2 and 
34.2 (median 34 and 33) years, respectively ( p = 0.0029).
Clinical characteristics (Table 2), differed among the three groups. Baseline CD4 counts 
were greater in the ineligible and waiting groups compared to the treated group (medians 
Group 1 = 386, Group 2 = 353, and Group 3 = 176; p<0.0001). In contrast, current CD4 
counts were comparable between the ineligible and treated groups and lowest among the 
awaiting group (medians Group 1 = 315, Group 2 = 145, and Group 3 = 327; p<0.0001). A 
high proportion of the treated (70%) and waiting groups (74%) had a WHO clinical stage 3 
or 4 diagnosis which varied significantly between the three groups ( p<0.0001). The mean 
number of symptoms reported at baseline were highest in the treated group and lowest in the 
ineligible group ( p = 0.0001). This trend reversed at the time of the study as the ineligible 
group reported the highest number of symptoms ( p<0.0001). The mean number of current 
AIDS-related symptoms and illnesses reported were higher and comparable between the 
ineligible (5.8) and waiting groups (6.0) and lower in the treated group (5.0) ( p = 0.053).
Quality of life (QOL) trends
For all MOS-HIV QOL domains, except social function, mean scores were highest, 
indicating best QOL, in the treated group (Table 3). Eight of the 11 mean domain scores 
were significantly different for the three groups: health perceptions, bodily pain, role 
function, vitality, health distress, cognitive function, QOL, and health transitions (all at p< 
0.0001 except for role function p = 0.01). Physical function and mental health domain scores 
were not significantly different for the three groups although there was a trend toward higher 
scores in the treated group. The overall mean score for the entire questionnaire was 
significantly highest in the treated group ( p<0.0001). The mean mental health summary 
(MHS) score was the highest in the treated group ( p<0.0001). The mean physical health 
summary (PHS) score was not statistically different for the three groups ( p < 0.74).
On multivariate analysis (Table 3) all of the unadjusted QOL domain scores except for role 
function remained significantly better in the treated group (all p<0.05). The mean and MHS 
adjusted scores were again significantly better in the treated group ( p<0.0001). Adjusted 
PHS scores remained insignificantly different in the three groups.
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Psychosocial measures
Psychosocial measures were most positive in the treated group (Table 4). Women on ART 
scored most favorably on the UCSF CAPS depression scale with a mean score of 14.32 out 
of 28, while the ineligible group scored 17.87 and the waiting group 16.70 ( p = 0.002). 
With the SSQ14, similarly, the treated group had a mean score of 26.01 out of 48 while the 
other two groups scored approximately 30 each ( p = 0.002). The median number of people 
a woman disclosed her HIV status to was five in the treated group, three in the ineligible and 
waiting groups ( p = 0.0006). The groups scored similarly on the perceived social stigma 
scale but did differ slightly with their scores on the experienced social stigma scale, with the 
groups scoring a mean of 13.94, 14.90, and 15.98 out of a possible 24 for Groups 1, 2, and 3, 
respectively ( p = 0.05). Their mean scores on the self-esteem scale did not differ 
significantly though the treated group had the highest mean score. A multivariate analysis 
revealed the treated group had the most favorable scores on the depression and SSQ14 
scales (both p<0.001; Table 4).
Quality of life (QOL) and CD4 count as functions of duration of antiretroviral therapy (ART)
Among the women on ART there is a non-significant trend toward increased QOL with 
increasing duration of ART (Figures 2a,b, p > 0.05). However, there is a more robust 
correlation between change in CD4 counts and treatment duration (Figure 3) with the 
Spearman correlation coefficient for change in CD4 count, current minus baseline, and 
duration on ART of 0.55 (p<0.0001).
Predictors of Quality of life (QOL)
A step-wise linear regression model was carried out with the three different summary scores 
of QOL: overall mean, PHS, and MHS (Table 5). Treatment, higher education, lower 
symptoms and illnesses in the last year, higher CD4 count, lower WHO clinical stage, and 
lower depressive symptoms were significantly associated with better mean QOL score. Only 
lower symptoms and illnesses and lower WHO clinical stage were significantly associated 
with better PHS. Treatment, greater number of household goods, higher CD4 count, and 
lower depressive symptoms were significantly associated with better MHS.
Discussion
Our study findings indicate that women on ART had better QOL than women not on ART, 
consistent with prior studies in Africa (Jelsma et al., 2005; Stangl et al., 2007). As expected, 
CD4 counts improved and symptoms abated on ART and the treated women had 
significantly lower depressive symptoms. The effect of treatment on QOL remained after 
adjusting for socio-economic status (SES; age, education, household goods, and religion), 
clinical (number of symptoms, CD4 count, and clinical stage), and psychosocial factors 
(depression and number of people disclosed to). Stangl et al. (2007) found economic 
dependence predictive of QOL at follow-up, which was not directly measured in our cohort. 
Nonetheless, our study population’s socio-economic homogeneity may have reduced our 
ability to assess the impact of SES on QOL. Generally speaking, aside from viral load, 
which was not measured in our study, it is unlikely that other clinical variables impact QOL. 
Therefore, there are likely other psychosocial factors, such as hopefulness or fear, which 
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mediate the association between treatment and perceived QOL. In addition, that the social 
function domain remained constant across the three groups may imply that social 
connectivity in this community is independent of health status.
Treatment is more robustly associated with mental health, while disease status is more 
closely associated with physical health. Significant predictors of PHS scores were number of 
self-endorsed AIDS-related sign and symptoms and baseline WHO clinical staging, not 
treatment itself. The MHS scores were highest and the levels of depression lowest in the 
treated group compared to ineligible and waiting groups, both unadjusted and adjusted. As 
previously noted, we did not find a significant difference on PHS scores between treated and 
untreated women. Treatment may, therefore, more rapidly improve mental health than 
physical health. Women on treatment may also have greater expectations of being well and 
expect more explicit gains in physical health. Thus, despite lower symptoms and higher 
current CD4 counts, the treated women perceive their health to be relatively worse than the 
untreated women. Additionally, treatment may have negative effects on PHS due to its side 
effects and toxicities. Lastly, patients are known to emphasize mental health rather than 
physical functioning on QOL questionnaires (Smith et al., 1999).
Factors predictive of better QOL scores were: treatment; clinical factors (e.g., fewer AIDS-
related symptoms, higher CD4 counts, and lower clinical staging); and psychosocial factors 
(e.g., lower depression). Socio-economic factors (e.g., higher education and greater number 
of household goods) predicted higher QOL scores in only one of the three summary scores. 
Therefore, we cannot generalize the significance of these factors’ impact to all of the 
domains of QOL. Consistent with our findings, Stangl et al. (2007) found similar clinical, 
socio-economic, and psychosocial factors predictive of better QOL. A reason for our limited 
ability to detect other SES and psychosocial predictors may reflect the sociocultural context 
in which we conducted the study (i.e., the homogeneity of our study population). Thus, 
future studies need to include QOL assessments that are culturally tailored to the 
Zimbabwean context, enroll socially heterogeneous groups, and include men to further 
assess the influence of socio-economic factors on QOL in Zimbabwe.
We report a unique finding that the QOL scores were similar for HIV-positive women 
ineligible for treatment and those with AIDS awaiting treatment. We anticipated lower QOL 
scores among women with AIDS awaiting treatment compared to those without AIDS and 
those already on treatment. However, the two groups of women not receiving ART had very 
similar QOL as well as depression scores, despite the significant differences in symptoms 
and CD4 counts. One explanation for this finding may be that women with HIV are 
vulnerable to social and individual stressors that impact their mental and physical health, 
regardless of differences in symptoms and CD4 counts. Moreover, tenuous access to ART in 
a struggling economy may impact psychosocial health and therefore overall QOL, 
particularly among the ineligible women. For instance, they may feel ignored or unfairly 
treated. Regardless, all HIV-positive women require social support and programming to 
address their QOL and psychosocial needs. Additionally, the finding of marked 
improvement in QOL and mental health associated with treatment argues for greater access 
to ART. In fact, CD4 levels which trigger treatment have recently been raised in the USA 
(Department of Health and Human Services, 2008) and many resource-limited countries are 
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considering changing their guidelines to provide treatment for HIV-infected individuals with 
≤350 CD4 cells/mm3. Fifty-five percentage of the ineligible women in our study had a CD4 
count less than 350 cells/mm3 at study entry and we welcome the prospect of broader access 
to earlier treatment in order to improve HR-QOL.
The aggregate QOL scores of the Zimbabwean women in this study are lower than those of 
other cohorts in SSA. For example, Stangl et al. (2007) found that the baseline QOL scores 
ranged from 20 to 66 and the 12-month follow-up scores ranging from 58 to 94. Scores in 
our waiting group ranged between 17–69 and 38–66 in the treated group. The lower scores 
in these Zimbabwean women may highlight the social, economic, and political hardships 
they currently confront. Taylor et al.’s (2009) cohort of rural Zimbabwean men and women 
with presumed HIV infection had domain mean scores similar to ours, ranging from 30 to 
62.
Strengths and limitations of study
This study adds to the growing literature on psychosocial impact of ART. Psychosocial 
measures such as depression, disclosure, stigma, self-esteem, and QOL were assessed with 
standardized, validated tools, with a reasonable sample size.
While the treated group demonstrated higher QOL scores compared to those not yet on 
treatment, we cannot ascertain if higher scores were due to treatment given the study’s 
cross-sectional design. The addition of focus groups or in-depth interviews may yield more 
information on psychosocial factors impacting QOL. The convenience sample may have 
introduced a healthy cohort bias of the women being healthy enough to attend the clinic; 
conversely, others presented with complaints. Some women may have over-reported their 
symptoms or negative experiences in the hopes of receiving more medical attention. For the 
women in the ineligible and waiting groups, our study also did not capture their 
interpretation of the gravity of their HIV disease, their perceived likelihood of getting 
treatment, or their number on the “waitlist.” These factors may better explain the role of 
hopefulness and self-perception on psychosocial health.
Future directions
This study highlights the need for further research on QOL out comes in various groups of 
HIV-positive individuals, especially those who are ineligible or awaiting treatment. Our 
findings suggest QOL benefits and depression reduction with ART. Qualitative studies are 
needed to better characterize the psychosocial mediators of ART’s impact on QOL. 
Knowing whether the trends observed in our study hold true in other sub-Saharan African 
settings would help in prioritizing resources and developing policies.
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Figure 1. 
Participant recruitment.
Patel et al. Page 11
AIDS Care. Author manuscript; available in PMC 2015 May 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
(a) Physical health summary (PHS) and mental health summary (MHS) scores as functions 
of duration on antiretroviral (ARV) treatment for the treated group only (n = 96). *Spearman 
rank correlation coefficients, both p > 0.05. (b) Mean QOL scores as a function of duration 
on antiretroviral (ARV) treatment for the treated group only (n = 96). *Spearman rank 
correlation coefficients, p > 0.05.
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Figure 3. 
Change in CD4 counts (current minus baseline) as a function of duration on antiretroviral 
(ARV) treatment for the treated group only (n = 96). *Spearman rank correlation 
coefficients, p<0.0001.
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Table 5
Potential predictors of QOL summary scoresa ( p-values only).
Variable Mean QOL score PHS score MHS score
Treatment groups <0.0001 0.86 <0.0001
Age categories 0.34 0.44 0.19
Education categories 0.018 0.37 0.063
Household goods categories 0.062 0.69 0.014
Religion 0.71 0.43 0.24
Number of self-endorsed AIDS-related symptoms/illnesses in the last year 0.0002 <0.0001 0.10
Current CD4 count categories 0.0007 0.32 0.0010
Baseline WHO clinical stage 0.045 0.0036 0.38
Duration since first HIV-positive test, categories 0.91 0.25 0.37
Number of people disclosed HIV status to, categories 0.97 0.28 0.44
Shona symptom questionnaire score categories <0.0001 0.54 <0.0001
aConducted using a backward stepwise linear regression model.
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